The most common mood disorders are major depressive disorders and bipolar disorders (BD). The pathophysiology of BD is complex, multifactorial, and not fully understood. Creation of new hypotheses in the field gives impetus for studies and for finding new biomarkers for BD. Conversely, new biomarkers facilitate not only diagnosis of a disorder and monitoring of biological effects of treatment, but also formulation of new hypotheses about the causes and pathophysiology of the BD. BD is characterized by multiple associations between disturbed brain development, neuroplasticity, and chronobiology, caused by: genetic and environmental factors; defects in apoptotic, immune-inflammatory, neurotransmitter, neurotrophin, and calcium-signaling pathways; oxidative and nitrosative stress; cellular bioenergetics; and membrane or vesicular transport. Current biological hypotheses of BD are summarized, including related pathophysiological processes and key biomarkers, which have been associated with changes in genetics, systems of neurotransmitter and neurotrophic factors, neuroinflammation, autoimmunity, cytokines, stress axis activity, chronobiology, oxidative stress, and mitochondrial dysfunctions. Here we also discuss the therapeutic hypotheses and mechanisms of the switch between depressive and manic state.
T HE
ETIOLOGY OF bipolar disorder (BD) remains uncertain; both genetic background and environmental factors, such as stressful life events or substance abuse, are related to the risk of development of BD. 1 Insights into the processes underlying neuroprogression in BD have been provided by studies examining genetic and epigenetic changes, structural and functional changes in the brain, damage in neuronal circuits, disturbed circadian rhythms, changes in immune and endocrine systems, impairment in neuronal plasticity and resilience, increased apoptosis, disturbances of synaptic transmission and signal transduction, activation of neurotoxic mechanisms, and changes in neurogenesis. 2 Pathways underlying neuroprogression in BD include the dopaminergic system, inflammatory cytokines, oxidative and nitrosative stress, mitochondrial dysfunction and endoplasmic reticulum stress, alterations in cAMP response element-binding protein (CREB) and neurotrophic system, dysregulation of calcium signaling, neuroinflammation, autoimmune processes, tryptophan and tryptophan metabolites, and hypothalamic-pituitary-adrenal (HPA) axis dysregulation ( Fig. 1) . [3] [4] [5] Current knowledge provides the background for formulation of several biological hypotheses of BD based on the identification of biomarkers for vulnerability, disease expression and course, and treatment response. Biomarkers for BD are still being researched: structural brain changes are searched for using neuroimaging methods; polymorphisms in a number of susceptibility genes have been discovered in genetic studies; and neurochemical biomarkers are studied in periphery above all. 6, 7 Further research is needed to validate these hypotheses and potential biomarkers prior to using them for clinical purposes. In this article we summarize our view of valid biological hypotheses for BD based on findings from brain neuroimaging, genetics, neurophysiological, neurochemical, and neuroimmuno-endocrinological approaches.
NEUROIMAGING
Structural imaging studies in patients with BD have identified anatomical and neuropathological abnormalities, which are associated with a neuroprogression. Moreover, previous mild traumatic brain injury has been identified as a risk factor for development of heterogeneous neuropsychiatric diseases, including BD. 8 Disruptions to cortico-striatal-limbic circuits are the most straightforward method of describing the pathophysiology and symptomatology of affective disorders. [9] [10] [11] Morphometric measurements discover in BD patients enlargement of lateral and third ventricles after several manic episodes, 12 progressive decline in hippocampal, fusiform, and cerebellar gray matter density after repeated episodes, 13 subregion-specific gray matter volume reductions in the prefrontal cortex, 14 and increased rates of deep white matter hyperintensities. 15 Neuroimaging studies have consistently demonstrated association of grey matter reduction in left rostral anterior cingulate cortex and right frontoinsular cortex thickness; that is, the most robust grey matter reductions in BD occur in anterior limbic regions, which may be related to executive control and emotional processing abnormalities. 16 In a large study of 1710 BD patients and 2594 healthy controls, the volumes of the nucleus accumbens, amygdala, caudate, hippocampus, globus pallidus, putamen, thalamus, and lateral ventricles were measured. BD patients have been found to have volumetric reductions for the mean hippocampus and thalamus and enlarged lateral ventricles. 17 However, brain volume may be altered by environmental factors, including medication. Imaging data suggest that decreased activity in prefrontal cortical areas may result in inadequate modulation of limbic/subcortical areas, which contributes to depressed mood and inadequate cognitive coping. Both regional gray-matter and white-matter changes appear to be present relatively early in BD development. 18 Functional magnetic resonance imaging (fMRI) confirmed that excessive activation in brain regions associated with emotional regulation may contribute to the affective symptoms of BD. Altered brain activation was identified in various regions in the cortico-limbic pathways; the most consistent findings were overactivation of the amygdala, striatum, and thalamus. 19 All studies using fMRI in BD supported the cortico-limbic hypothesis and suggest that connectivity can be more complex and that intra-regional disturbances should also be studied. 20 
GENETICS
Genetic studies have suggested that many chromosomal regions and candidate genes are related to susceptibility to BD with each gene exerting a mild to moderate effect. 21 It is accepted that understanding of changes in regulation of gene expression (caused by mutations, polymorphisms, and epigenetic changes) of specific components of signaling pathways may significantly contribute to recognition of processes responsible for disease onset and progression. Twin and adoption studies consistently demonstrate a genetic influence on all major psychiatric disorders. 22 Based on twin studies, heritability of BD was estimated at 85%. 23 A number of plausible candidate genes have been previously associated with BD, including genetic polymorphisms of key signaling components, such as serotonin transporter (5-HTT, SERT), dopamine transporter (DAT), brain-derived neurotrophic factor (BDNF), tryptophan hydroxylase (TPH), catechol-Omethyltransferase (COMT), D-amino acid oxidase activator (DAOA), and mutations of mitochondrial DNA (mtDNA). [24] [25] [26] BD is seen as polygenic disorders underpinned by many genes of small effect size. Gene expression analysis in the post-mortem brains of BD patients indicates alterations in glutamate receptors, mitochondria-related genes, chaperone genes, oligodendrocyte genes, and markers of GABAergic neurons. 27 Epigenetic modifications and gene-environment interactions are studied to explain genetic vulnerability that triggers BD.
The meta-analysis of genetic association studies on BD showed the lack of robust findings. Single polymorphisms in four different genes, BDNF, DRD4, DAOA, and TPH1 (encoding BDNF, dopamine receptor D 4 , DAOA, and TPH 1, respectively) were found to be nominally significant; however, none of these findings were significant after correction for multiple testing. In a systematic review of genome-wide gene expression studies of BD, 11 genes were found to be significant after correction for multiple testing. Among these were FKBP5 (encoding FK506 binding protein 5, which plays a role in immunoregulation, protein folding and trafficking) and WFS1 (encoding wolframin, which acts as a cation-selective ion channel). Both of these genes have been previously implicated in mood disorders. 28 Findings in meta-analyses of BD depend on the method that was used to combine data. Recently, among the 226 genes with significant effect in BD, nine differed in expression in the dorsolateral prefrontal cortex in patients with BD: CACNA1C (encoding calcium channel, voltage-dependent, L type, α1C subunit), DTNA (encoding dystrobrevin α), FOXP1 (encoding forkhead box protein P1), GNG2 (encoding guanine nucleotide-binding protein G i /G s /G o subunit γ-2), ITPR2 (encoding inositol 1,4,5-trisphosphate receptor, type 2), LSAMP (encoding limbic system-associated membrane protein), NPAS3 (encoding transcription factor neuronal PAS domain protein 3), NCOA2 (encoding nuclear receptor coactivator 2), and NTRK3 (encoding tropomyosin receptor kinase C). Intracellular signaling pathways have been identified that contribute to risk for BD using genes with consistent evidence for association in multiple genome-wide association studies (GWAS): glutamate receptor signaling, phospholipase C (PLC) signaling, corticotrophin-releasing hormone (CRH) signaling, endothelin 1 signaling, cardiac β-adrenergic signaling, and cardiac hypertrophy signaling. The pathway with the strongest evidence is the CRH signaling pathway. 29 In another study, a meta-analysis confirmed a significant gene effect for 46 genes (65 variants) in BD, whereas the strongest gene effects for BD were reported for 21 genetic variants. The biological pathways implicated included cell activation and proliferation and signal transduction, apoptosis and chromatin modification, chemokine signaling, glutamate signaling and regulation, immunological response, cell adhesion and migration, neurotransmitter degradation and tumor suppression. 30 The GWAS studies confirmed a polygenic contribution to risk of BD development. Preliminary analyses of whole genome/exome sequencing have supported the role of calcium, CREB, and potassium channels signaling pathways in BD. 31 Several common polymorphisms, including variants of genes CACNA1C, TENM4 (encoding teneurin transmembrane protein 4, a protein promoting neurite outgrowth and cell adhesion), NCAN (encoding neurocan, a significant component of the extracellular matrix), and ANK3 (encoding ankyrin G, a scaffold protein required for the normal clustering of voltage-gated sodium channels at the axon hillock and for action potential firing), are significantly associated with BD. 32, 33 The number of significant common single nucleotide polymorphism (SNP) associations detected in GWAS should rise as sample sizes increase. Recently, two novel loci associated with BD have been identified in the GWAS of 40 000 individuals.
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NEUROTRANSMITTERS
The biological hypotheses of mood disorders are under development. 35 The monoamine hypothesis was initially formulated as catecholamine 36 and/or indolamine 37 deficiencies in the brain; that is, as the neurotransmitter hypothesis. Later, the monoamine hypothesis was revised to include the role of neurotransmitter receptors, transporters, catabolizing enzymes (monoamine oxidase [MAO] , and COMT), and other brain neurobiological systems. 10, [38] [39] [40] The monoamine hypothesis of mood disorder posits that an imbalance in monoaminergic neurotransmission in the central nervous system is causally related to the clinical features of depression or mania. This hypothesis has been supported by mechanisms of action of antidepressants. 35, 41, 42 Moreover, many candidate genes associated with BD encode compounds influencing directly the monoamine neurotransmitter systems, for example, SLC6A4 (encoding serotonin transporter), TPH2, DRD4, SLC6A3 (encoding dopamine transporter), MAOA (encoding MAO type A, MAO-A), and COMT. [43] [44] [45] The advanced monoamine hypothesis 46 supposes that serotonin or norepinephrine concentrations in the brain are regulated by MAO-A activity, and that the severity of symptoms of depression is linked to changes in the activity of monoamine transporters in specific brain regions. The hypothesis has been supported by observation of elevated MAO-A density and reduced 5-HTT density during depressive episode. [46] [47] [48] Hyperdopaminergic function has been reported in BD. A dopamine hypothesis of BD was formulated that suggests a role of increased dopaminergic transmission in mania and the converse in depression. 49, 50 The hypothesis is supported by the fact that altered availability of dopamine transporter has been accepted as a biomarker for BD. 51 Monoamine depletion studies, genetic association studies, PET studies, and mechanism of action of antidepressants supported an important role of disturbed monoamine neurotransmission in the pathophysiology of mood disorders but have not evidenced the primary role of monoaminergic system in development of the disorder. The molecular changes underlying imbalances of neurotransmission in BD are not agreed upon; it is hypothesized that alterations in excitatory amino acid transporters, 5-HTT, and dopamine transporter contribute to altered glutamatergic and monoaminergic function in BD patients. 52 The hypothesis that the dysfunctional muscarinic acetylcholine system is involved in the pathophysiology of BD has been supported by the finding that there is reduced muscarinic acetylcholine M 2 receptor binding in subjects with BD, 53 which could be accounted for by a reduction in M 2 receptor affinity caused by genetic variation in the gene for M 2 receptor. 54 Glutamate and GABA systems are posited in the pathophysiology of major depression and BD that extends beyond monoaminergic dysfunction. 55 Glutamate levels were increased in the post-mortem brains of subjects with BD, while the glutamate/glutamine ratio was decreased following valproate treatment, and GABA levels were increased after lithium treatment. The balance of excitatory/inhibitory neurotransmission seems to be central to the BD. 56 A meta-analysis confirmed that brain glutamate + glutamine levels are elevated in BD patients, 57 which supported an important role of glutamate in the pathophysiology of BD. Due to the role of glutamate in neurotransmission, brain energy metabolism, astrocyte function, neurotoxicity, neuroplasticity, and learning, the glutamate hypothesis of mood disorders is expected to complement and improve the prevailing monoamine hypothesis. 58, 59 The hypothesis is supported by the observation that antagonists of glutamate N-methyl-D-aspartate (NMDA) receptor produce rapid antidepressant effect. 60, 61 
NEUROTROPHIC FACTORS
Neurotrophic factors are growth factors that promote neuroplasticity, neurogenesis, survival, differentiation, and maintenance in healthy and regenerating brain cells. They include nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). They are two classes of neurotrophic receptors: low-affinity nerve growth factor receptor (LNGFR, p75 neurotrophin receptor) and a family of high-affinity tropomyosin receptor kinase (Trk, also tyrosine receptor kinase; types TrkA, TrkB, and TrkC [62] [63] [64] [65] [66] An important intracellular regulator of apoptosis and cell survival in the developing, adult, and injured nerve cells is the p53 protein family. 67 Neurotrophin signaling and vesicular transport is linked; disturbances of vesicular transport lead to disturbed neurotrophin signaling and to diseases of the nervous system. 68 Disturbances in activities of neurotrophic factors and related impairment in plasticity and resilience in brain cells has been reported in BD. Attention is paid to neurotrophins and other growth factors that regulate function of brain cells, such as BDNF, GDNF, insulin-like growth factor 1 (IGF-1), and vascular endothelial growth factor (VEGF).
69,70
Brain-derived neurotrophic factor
Post-mortem brains of BD patients have shown significantly decreased protein and mRNA levels of BDNF in the frontal cortex, which indicates that decreased BDNF is part of the pathophysiology of BD. 71 Several meta-analyses have shown that there may be a correlation between low BDNF levels and the emergence of BD. [72] [73] [74] A systematic review and meta-analysis confirmed that peripheral BDNF levels in BD are consistently reduced during manic and depressive episodes and plasma levels of BDNF are recovered after treatment for acute mania, that is, the BDNF plasma or serum levels are not different in euthymia when compared to controls. 73, 75, 76 Thus, reduction in serum BDNF may be a potential biomarker of acute episodes and could differentiate patients in a manic or depressive episode from those in the euthymic phase. Moreover, serum BDNF may distinguish BD from unipolar depression, 77 may be a biomarker of MD progression and severity, 73, 75, 78 may discriminate initial and advanced BD episodes, 79 and may reflect response to treatment. 76, 80 The role of BDNF in the pathophysiology of BD has been supported by findings that BDNF mRNA is decreased in cingulate and temporal cortices and in the hippocampus 81, 82 and that precursor protein proBDNF encoded by the BDNF gene has been suggested as a biomarker of mood disorders. 83 Note that BDNF levels in the blood could be derived from its production by both brain and peripheral tissues, such as skeletal muscle, liver, and the cardiovascular system, and BDNF in the blood is stored predominantly in platelets. 84 Nevertheless, intact BDNF in the peripheral circulation crosses the blood-brain barrier (BBB) by a high-capacity saturable transport system 85 and blood and plasma BDNF concentrations reflect brain-tissue BDNF levels. 86 BDNF plays a key role in the pathophysiology of stress-related mood disorders. Acute stress, such as partial sleep deprivation, induced a fast increase in BDNF serum levels, whereas long-term stress led to sleep disturbance and depression as well as decreased BDNF levels. 87 The role of BDNF in the pathophysiology of BD has been evidenced by elevation of serum and brain BDNF levels by antidepressant, mood stabilizers, and antipsychotics, 88, 89 including lithium. 90 The Val66Met polymorphism (refSNP Cluster Report: rs6265) of the BDNF gene is a functionally relevant SNP affecting the secretion of BDNF and is implicated in differences in hippocampal volumes. The hippocampal volumes were reduced significantly in association with the presence of the BDNF met allele and with BD diagnosis. 91 However, a systematic meta-analytical review of findings on the impact of the rs6265 SNP on hippocampal volumes in patients with BD suggested that there is no association between this BDNF polymorphism and hippocampal volumes. 92 Another meta-analysis was performed to determine the overall strength of associations between BDNF genetic polymorphism Val66Met and susceptibility to BD. It was concluded that there is no compelling evidence to support Val66Met polymorphism in the BDNF gene playing an important role in the susceptibility to BD. 93 However, plasma BDNF levels were significantly negatively correlated with depression scores in patients with BD. It was supposed that plasma BDNF in BD is not affected by BDNF Val66Met gene variants, but by progression of the illness itself.
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Other growth factors
There are few studies that evaluate the role of NGF in the pathophysiology of BD and the results are inconsistent. 70 For example, decreased plasma NGF was reported in BD in the manic episode, 95 but another study stated significantly higher IGF-1 in patients with bipolar I disorder and no changes in NGF. 96 Effects of NT-3 and NT-4 also require more research. Serum NT-3 levels in drug-free and medicated patients were found to be increased when compared with controls and serum NT-3 levels did not differ between drug-free and medicated patients. 97 Serum concentrations of NT-4 were reported to be significantly higher in BD patients than in controls. 98 At baseline, in bipolar depressed patients, there were no differences between responders and non-responders to treatment with ketamine in serum BDNF, NGF, NT-3, NT-4, or GDNF. 99 A study of GDNF in BD revealed that different stages of the disorder and drug treatment can alter activity of GDNF. 70 Lower GDNF concentrations might be involved in the pathophysiology of BD and drug treatment increases the GDNF. 100 The evidence has been provided that IGF-1 plays a role in the pathophysiology of BD. 70 The IGF1 gene has been identified as a candidate gene for susceptibility to BD. 101 Peripheral levels of IGF-1 were found to be unchanged in patients with BD compared to controls 102 ; however, it seems that lithium may regulate IGF-1 levels. 103 Low expression of IGF1 has been suggested as a putative biomarker for lithium unresponsiveness. 104 Plasma VEGF levels were elevated in patients with a manic episode of BD, which may be associated with a neuroprotective role for VEGF. 105 Increased expression of the VEGF gene was also found in a depressive episode of BD compared to healthy control subjects. 106 Lithium treatment led to decrease of VEGF mRNA levels. 107 These results indicate that VEGF may vary with the episode of the disease and may be associated with the pathophysiology of BD. 70 It was reported that some members of the neurotrophin family, such as NGF, NT-3, and NT-4, can cross the BBB; NGF had the fastest influx rate and NT-3 the slowest. 108 CNTF is saturably transported across the BBB from blood to brain. 109 IGF-1 enters the CNS by a saturable transport system at the BBB, which functions in synchrony with IGF-binding proteins in the periphery to regulate the availability of IGF-1 to the CNS. 110 It indicates that peripheral administration of some neurotrophins could have therapeutic effects within the CNS. In contrast, GDNF and VEGF do not cross the BBB 111 ; VEGF enhances angiogenesis and promotes BBB leakage in the ischemic brain.
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Neurotrophic hypothesis
Neurotrophic, neuroplasticity, and neurogenesis hypotheses were formulated, supposing a key role of post-receptor and intracellular processes (regulating intercellular and intracellular signaling) in the development of mood disorders. These hypotheses emphasize the role of stress, growth factors and neurogenesis in the pathophysiology of BD 69, [113] [114] [115] [116] and they are supported by neurotrophic effects of various antidepressants and mood stabilizers. Wnt signaling pathway and GSK-3 activity have been implicated in both regulating neuroplasticity and neuroprotection. 117, 118 The neurogenesis hypothesis of depression proposes that depression can arise from impaired hippocampal neurogenesis and that antidepressants stimulate neurogenesis. Coupling of hippocampal neurogenesis to pathophysiology of depression requires further research to be confirmed. 2, [119] [120] [121] Neuroprogression is an important mechanism of BD, and neurotrophins are key regulators of neurogenesis and neuroplasticity. 2, 70, 122 The neurotrophic hypothesis 69, [113] [114] [115] postulates that mood disorders, such as BD, are associated with a lower activity of neurotrophic factors, such as BDNF. Vulnerability to depression can arise as a result of neuronal damage (e.g., after chronic stress, long-term increased levels of glucocorticoids, ischemia, hypoglycemia, viral infections, and action of neurotoxins) and therapeutic effects of antidepressants may consist in activation of higher expression of neurotrophin BDNF and its receptor TrkB (e.g., through activation signaling pathways linked to monoaminergic systems) leading to increased neuronal plasticity, reactivation of cortical plasticity, and resumption of neuronal functions.
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NEURO-IMMUNO-ENDOCRINOLOGICAL APPROACH
The initial episodes of BD are often precipitated by psychosocial stressor, which activates the HPA axis and elevates cytokines. Cytokines, dopamine autoxidation, increased activation of glutamate ionotropic receptors, and mitochondrial dysfunction cause increased production of ROS and oxidative stress. Cellular stress responses include upregulation of molecular chaperones to protect biomolecules from degradation. 124 The innate immune response in the brain seems to be a potentially pathogenic factor in a number of CNS diseases that do have activated microglia and astrocytes (i.e. neuroinflammation is accepted as a pathogenic factor in these diseases). 125, 126 The exchange of signals between neurons and the glial cells at the CNS level is achieved by means of chemokines, cytokines and the complement system. Dysregulation of cytokines has been linked to many diseases, including BD. The immunological disturbance along the bipolar spectrum was most severe in BD-I patients. 127 
Autoimmunity
Comorbidity of autoimmune diseases and BD suggests a possible autoimmune etiology. In a cohort of 9920 cases of BD in Denmark, the degree was determined, to which 30 different autoimmune diseases are antecedent risk factors for BD. 128 The significant familial association (genetic linkage) of autoimmune diseases to BD was not found (except for pernicious anemia); however, the data suggest that some autoimmune diseases, such as Guillain-Barré syndrome, Crohn's disease, and autoimmune hepatitis, may precede onset of BD. This means that, in some cases, the onset of BD arises in connection with the inflammatory process associated with these autoimmune diseases.
Association of BD with autoimmune diseases may be partially explained by the finding that the frequency of regulatory T lymphocytes (CD4+ CD25+ Foxp3+) (cells related to the suppression of the proliferation of effector T cells and suppression of excessive misguided immune responses, including inhibition of the development of autoimmune diseases) was reduced in BD patients. 129 
Neuroinflammation
Chronic neuroinflammation, caused by neurotoxins, autoimmunity, aging, traumatic brain injury, microbes and viruses, is associated with several mental and neurodegenerative diseases. Both brain cells (microglia, astrocytes, and neurons) and peripheral immune cells have been implicated in neuroinflammation and the resulting oxidative and nitrosative stress. Neuroinflammation is typically associated with activation of microglia, which are major sources of ROS in the brain, and play crucial roles in various brain diseases. [130] [131] [132] Pro-inflammatory cytokines do not freely cross the BBB under physiological conditions. Thus, it is still unclear how the changes in the periphery affect pro-inflammatory processes in the CNS. Post-mortem studies have shown that BD patients present increased pro-inflammatory and decreased anti-inflammatory markers in the frontal cortex. 133, 134 Recently, BD has been discussed to be characterized by glial pathology and neuroinflammation. 135, 136 BD patients present an episode-related inflammatory syndrome 137 (i.e. pro-inflammatory state may be associated with BD). Really, the immune dysfunctions and pro-inflammatory state have been implicated in the pathophysiology of BD, which was documented by increased frequency of autoimmune diseases, distinct immune cell profile, cytokines released by stimulated mononuclear cells, elevated levels of circulating cytokines, and inflammatory changes in the CNS. 4, 138 Moreover, after injury and sustained release of inflammatory factors, permeability of BBB may be increased and circulating blood components and peripheral immune cells may enter into the brain, which contributes to chronic neuroinflammation and neurodegeneration. 139 The molecular regulation of neuroinflammation is strongly influenced by epigenetic mechanisms (i.e. by DNA methylation, histone modification, and noncoding RNA). 140 The calcium-binding protein B (S100B), a growth and differentiation factor released by astrocytes and oligodendrocytes, was found to be significantly elevated in BD during episodes of mania and depression, but not in euthymic patients. 141, 142 Serum S100B has been linked to specific imaging parameters in human white matter. Powerful whole genome gene expression studies showed an increase in S100B gene expression in the hippocampus in BD. 143 Activation of microglia may mediate neuronal and glial cell injury and death through activation of pro-inflammatory factors, such as cytokines, chemokines, metalloproteinases, cytotoxic factors, or complement system proteins. 4, 144, 145 Upon activation, microglia can produce pro-inflammatory (at M1 polarization) or anti-inflammatory (at M2 polarization) cytokines. Mania and, to lesser degree, depression are associated with a proinflammatory state. 146 BD patients in manic episode had higher concentrations of interleukin (IL) 6 (IL-6), interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), IL-2, the soluble form of IL-6 receptor (sIL-6R), and soluble TNF receptor 1 -(sTNFR1), [147] [148] [149] [150] while IL-4 concentration was significantly lower than normal controls. 148 After treatment, IL-6 was normalized and TNF-α remained increased, which indicate that IL-6 might be a state marker of manic episode. 148 Inflammatory biomarkers are capable of discriminating the initial stages of BD from those in advanced stages (declined IL-10 and increased TNF-α in advanced BD stages). 151 TNF-α is a potential biomarker of BD progression. In addition, elevated levels of C-reactive protein were found during manic episodes as well as in the bipolar depressed group. 152, 153 The analysis of biomarkers in cellular supernatants confirmed increased in vitro production of cytokines IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IL-17 by isolated peripheral blood mononuclear cells stimulated with phytohaemagglutinin and confirmed the dominance of T-helper type 1 (Th1) cytokines in BD. 129 There were similarities in the pattern of cytokine alterations in schizophrenia, BD, and major depressive disorder during acute and chronic phases of illness. For example, plasma levels of sTNFR1 and von Willebrand factor (vWf ) were found to be significantly increased in both BD and schizophrenia compared to controls. 154 In summary, data about the association of BD with peripheral immune system dysfunction are conflicting in individual studies. BD patients presented both increased and decreased plasma levels of chemokines 155 and it was evidenced that the release of various interleukins is altered in BD. 156 Meta-analyses of blood cytokines have shown that levels of IL-2, IL-6, IL-10, TNF-α, soluble IL-2 receptor (sIL-2R), TNF-α, sTNFR1, sIL-6R, IL-4, and IL-1 receptor antagonist (IL-1RA) were significantly increased in acutely ill patients with bipolar mania compared with controls. [157] [158] [159] Following treatment of the acute illness, IL-1RA levels in bipolar mania decreased. In chronically ill patients, the levels of IL-6 were significantly increased in euthymic (but not depressed) BD compared with controls. The levels of IL-1β and sIL-2R were significantly increased in euthymic BD.
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HPA axis
There are evident abnormalities of HPA axis activity in BD. Hypercortisolism and neurocytotoxic effects of cortisol may be central to the pathogenesis of depressive symptoms and cognitive deficits; manic episodes may be preceded by increased concentrations of adrenocorticotropic hormone and cortisol. 160 A meta-analysis revealed moderate quality evidence of increased morning cortisol levels in BD compared to controls, which suggests long-term pathology of the HPA axis that supports stressvulnerability models of the disease. 161 A recent systematic review and meta-analysis of HPA axis activity in BD confirmed that BD is associated with abnormalities of stress-related pathways in the brain; 162 BD is associated with HPA axis hyperactivity (increased cortisol levels), most prominently in the manic episode, but also in remission. The meta-analysis showed that variants of HPA-axisrelated genes seem not to be associated with the direct risk of BD and HPA axis dysregulation and that HPA axis abnormalities should not be considered as an etiological factor or endophenotype of BD, but seem to be related to environmental risk factors.
Effects of glucocorticoids, increased due to activation of the HPA axis, on activity of cellular compounds included in neuroinflammation, neurotransmitter signaling pathways, or bioenergetics may participate in the pathophysiology of BD. Interference of excessive glucocorticoid with BDNF signaling may be accomplished through interaction of glucocorticoid receptors with TrkB. 163 Progressive HPA axis dysfunction might participate in the neuroprogression and the clinical and cognitive deterioration in BD. While HPA axis activity responds to pharmacological treatment, targeting of the HPA axis may improve the outcome of BD in the long term.
Metalloproteinases
Proteins of the matrix metalloproteinase family are involved in the breakdown of extracellular matrix in normal physiological processes. Matrix metalloproteinase 9 (MMP-9) has been implicated in neuroplasticity and a number of pathological conditions, including neuropsychiatric disorders, such as schizophrenia, BD, and multiple sclerosis. Moleculargenetic studies of the functional polymorphism of MMP9 gene demonstrated an association of the polymorphism with a predisposition to BD. 164 Bipolar patients, both during acute episode and in remission after depression, had significantly higher MMP-9 serum levels compared to those with manic episode and control subjects, 165 which indicates serum MMP-9 as a possible marker for staging of BD. MMP-7, which may be involved in regulation of inflammatory processes, was found to be altered specifically in mixed mood episodes of BD patients. 166 
Inflammatory hypothesis
The macrophage/T-cell hypothesis of depression states that chronically activated macrophages and T-cells in periphery and microglia in the brain produce inflammatory cytokines, which modify brain functions and, in conjunction with genetic and environmental factors, precipitate the symptoms of BD. 167 The hypothesis of a pro-inflammatory stateinduced BD supposes that elevated levels of a cytokine cause manic and depressive symptoms. The hypothesis has been supported by the finding that immune challenge with IFN-α during treatment of hepatitis C induces the depressive or manic symptoms in a significant number of patients. 168, 169 It is hypothesized that the immune system in BD is chronically activated by microglia, which lead to increased production of cytokines and the imbalance between the pro-inflammatory and the anti-inflammatory state of microglial activation results in mood disorders. Pro-inflammatory state is defined by increased activity of cytokines (IL-1β, IL-6, TNF-α) and chemokines (CCL2), release reactive oxygen species (ROS) and NO, activation of P2X purinoceptor 7 and toll-like receptors, and cyclooxygenase-2 (COX-2) upregulation. Antiinflammatory response to microglia activation is related to the release of IL-4, IL-10, IL-13, IGF-1, TGF-β, and BDNF, increased microglial phagocytosis, and increased synaptic pruning. 150 It is possible that microglial activation contributes to both pathophysiology of BD and treatment responses. 132, 135 The underlying mechanisms of the immune activation in BD may include both changes in frequency and activation of circulating lymphocytes. Defective neuroendocrine control over the immune system may partially explain increased circulating levels of pro-inflammatory cytokines in BD patients. 168 On the molecular level, it can be expected that cytokine signaling can influence neuro-glial interactions through ATP-gated ion channel P2X purinoceptor 7 156, 170 and the T-cells of BD patients had an increased phosphorylated extracellular signalregulated kinases (ERK) signaling. 129 Moreover, activated microglia may promote expression of IFN-γ, a potent activator of kynurenine pathway, whose role is described below.
New 'serotonin' hypothesis
Brain serotonin biosynthesis is carried out by hydroxylation and decarboxylation of the amino acid tryptophan. Catabolism of tryptophan in the kynurenine pathway may cause depletion of brain serotonin in depressive episode. Rate-limiting factor is the conversion of tryptophan to kynurenine, which is catalyzed by tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO). Tryptophan catabolites (TRYCAT) produced in the kynurenine pathway may be depressogenic and anxiogenic. Activation of the kynurenic pathway (labeled also as the TRYCAT pathway) may be associated with the development of depressive symptoms through both serotonin depletion and detrimental effects of TRYCAT, such as activation of oxidative pathways, mitochondrial dysfunctions, and neurotoxicity. 4, 171, 172 Changes in the kynurenine pathway in BD have been identified at the mRNA-expression, protein, and metabolite levels. Whether these changes represent biomarkers of disease or whether they represent disease causation is not clear; however, psychoses of several different etiologies involve activation of this pathway. The significant changes that had been identified for BD include increased kynurenine and TDO 173 (i.e. upregulation of the TRYCAT pathway). Nicotinamide, a kynurenine pathway end-product, was found to be significantly elevated in the anterior cingulate cortex of bipolar patients who committed suicide within the bipolar group. 174 IDO is induced by IFNγ, IL-6, TNFα, lipopolysaccharides, and oxidative stress. The new 'serotonin' hypothesis of depression 171 states that ROS and cellmediated immune activation (peripheral cell-mediated immune activation and microglial-mediated neuroinflammation), which is characterized by an increased production of IL-1β, IL-6, TNFα, and IFNγ, induce IDO and activate the kynurenine pathway. It leads to lower plasma and brain tryptophan (and thus lowered brain serotonin, N-acetylserotonin, and melatonin synthesis) and an increased synthesis of detrimental TRYCAT (e.g. kynurenine and quinolinic acid), both of which contribute to the onset of depression. 175 The TRYCAT pathway is also activated following induction of TDO by glucocorticoids, which are elevated in depression.
There is interconnection of peripheral and central immune, inflammatory, neuroendocrine, oxidative and nitrosative stress pathways; e.g., the responsiveness of T-cells to the immune suppressive effect of dexamethasone is attenuated in BD, independently on the current mood state. 176 
Chronobiological hypothesis
Rhythmicity is a fundamental property of living organisms. 177 Virtually all patients with BD display significant disruption of circadian rhythms, such as sleep, activity, hormonal secretion, and appetite, which suggest that circadian rhythms abnormalities may play a role in precipitating periodic episodes of depression and mania. Lower levels of melatonin were found in euthymic patients, depression episodes and even mania when compared with healthy controls. 178 The circadian system might play an important role in the pathogenesis of BD and this disorder should be effectively treated by melatonin or agomelatine.
Melatonin (N-acetyl-5-methoxy tryptamine) is a hormone that influences circadian and seasonal rhythms; however, melatonin is also a powerful antioxidant, metal chelator, and anti-inflammatory agent. 179 Melatonin secretion modulates the production of the thyrotropin and tuberalin hormone and induces synthesis of triiodothyronine (T3). Excessive hypothalamic T3 may mediate mania, whereas insufficient hypothalamic T3 may cause depression.
The hypothesis that internal desynchronization and changes in melatonin rhythmicity participate in the genesis of BD has been discussed. 180, 181 Disturbances of sleep timing are worse during mood episodes, but still apparent during euthymic periods. 182 Recently, a hypothesis regarding separate oscillators for morningness and eveningness has been formulated. The photoperiodic and circadian bifurcation hypothesis proposes that combined with genetic susceptibilities, abnormal light illumination triggers rapid-cycling BD, and perhaps most mania, by internal desynchronization or bifurcation of suprachiasmatic nucleus (SCN) circadian rhythms leading to photoperiod malregulation and excess hypothalamic T3 production. 183 Linkage of melatonin to the serotonin system may be through tryptophan metabolism as described above. There are several ways by which melatonin and dopamine interact and modulate one another. 184 These interactions and the antioxidant nature of melatonin may be beneficial in the treatment of monoamine-related mood disorders, such as BD. Due to the role of monoamine neurotransmission in mood disorders and melatonin role in modulation of circadian rhythmicity, a proper approach to studying the pathophysiology of mood disorders may be to consider the monoamine and melatonin systems as one integrated system.
Clock genes interact with each other in an intricate manner generating oscillations of gene expression. Genomic studies suggest an association of circadian clock genes (BMAL1, CLOCK, NPAS2, PER3, CRY1, RORA, and TIMELESS) with depressive disorder or BD. 185 Moreover, expression of circadian clock components was found to be affected by lithium treatment. 186 Transcription of the gene MAOA is regulated by the clock components BMAL1, NPAS2, and PER2, 187 which is another link between monoamine neurotransmission and circadian rhythms. The clock genes also provide a link between circadian rhythms and GSK-3β activity, which is an important factor in the etiology of BD. 188 In summary, altered circadian rhythms may be involved in the etiology of BD; however, it is © 2016 The Authors Psychiatry and Clinical Neurosciences © 2016 Japanese Society of Psychiatry and Neurology possible that both circadian disruptions and mood disorders are common effects of something else or the pleiotropic effects of common components.
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OXIDATIVE STRESS
Lowered antioxidant defenses (lowered concentrations of antioxidants, such as vitamin E, tryptophan, zinc, and coenzyme Q 10 ; lowered activities of antioxidative enzymes) and increased oxidative and nitrosative stress causing lipid peroxidation, oxidation and nitration of proteins or nucleic acids, damage to mitochondria and secondary autoimmune responses are evident in BD. 3, 175, 190, 191 Serum lipid hydroperoxides may be useful in the development of clinically relevant peripheral biomarkers of BD.
192 Meta-analysis of oxidative stress markers in BD confirmed that lipid peroxidation, DNA/RNA damage, and nitric oxide were significantly increased in BD patients compared to healthy controls. 193 However, no significant effect sizes were observed for the antioxidant enzymes and products of oxidative protein damage.
Processes that may play a role in the increased oxidative and nitrosative stress in BD include activation of immune-inflammatory and autoimmune pathways, modulation of antioxidant defense through activation of nuclear factor (erythroidderived 2)-like 2 (Nrf2), activation of TRYCAT pathway, glutamate toxicity due to depletion of intracellular glutathione, mitochondrial dysfunctions leading to increased production of ROS, and activation of toll-like receptors by lipopolysaccharides or psychosocial stressors. 194 Association of increased oxidative stress with lower BDNF levels has been confirmed in BD. Serum thiobarbituric acid reactive substances (TBARS), which are formed as a byproduct of lipid peroxidation and may be used as biomarkers or progression of BD, 141 were negatively correlated with serum BDNF levels in manic BD patients, but not in healthy volunteers. 195 There is a link between dysfunctional mitochondrial complex I, increased production of ROS, increased oxidative stress, and decreased levels of brain BDNF.
196
MITOCHONDRIAL DYSFUNCTIONS
Mitochondrial and metabolic dysfunctions may be involved in the pathophysiology of different neuropsychiatric disorders, including BD, 35, [197] [198] [199] [200] [201] [202] given the key role of mitochondria in the cell energy metabolism, apoptosis, oxidative stress and calcium homeostasis. Data provide evidence for abnormalities in mitochondrial structure and function in BD. Mitochondrial dysfunctions in BD include: (i) decreased mitochondrial respiration due to reduced activity of mitochondrial complexes in electron transport system; (ii) changes in mitochondrial morphology; (iii) increases in mtDNA polymorphisms, deletions or mutations; and (iv) decreased levels of high-energy phosphates and decreased pH in the brain. 203 Post-mortem brains of BD patients have shown decreased expression and activity of electron transport chain (ETC) and increased oxidative stress. BD is also associated with calcium dysregulation and apoptosis. Neuroimaging studies confirmed an impaired energetic metabolism in brains of BD patients. Mitochondrial dysfunctions in BD have been supported by genetic findings; however, BD is not a classic mitochondrial disorder and mitochondrial functions seem to be regulated rather by expression of nuclear genes. 204 Mitochondria are an important endogenous source of ROS. Increased oxidative and nitrosative stress is associated with mitochondrial dysfunction. 191 Damage of cellular functions due to increased oxidative and nitrosative stress and/or lowered levels of antioxidant protections are probably involved in the pathophysiology of depression. 3, 205, 206 Both mitochondrial dysfunction and neuroinflammation occur in BD. A potential link between mitochondrial dysfunctions and activation of the inflammatory system may be the nod-like receptor pyrin domain-containing 3 (NLRP3) inflammasome. 207 Increased production of ROS by mitochondria (e.g. due to dysfunction of complex I) causes activation of NLRP3 and caspase 1 and formation of inflammasome, which lead to activation of cytokines and alterations in neurotransmission.
BD is frequently comorbid with primary mitochondrial and metabolic disorders, and mitochondrial dysfunction has been implicated in its pathophysiology. A hypothesis of mitochondrial dysfunction in BD is based on findings of magnetic resonance spectroscopy that in the brains of BD patients, high-energy phosphates are decreased, lactate is elevated, and pH is decreased, which together suggest impaired oxidative phosphorylation, a decrease in total energy production and/or substrate availability, and a shift toward glycolysis for energy production. 208, 209 Moreover, proton magnetic resonance spectroscopy in patients with BD revealed decreased levels of N-acetylaspartate (NAA) in the basal ganglia; choline and creatine levels were not altered. 210 Oxidative stress is increased, calcium signaling is dysregulated, and mitochondrial complexes, especially complex I, are downregulated. The therapeutic effects of some drugs/mitochondrial modulators, which are putative neuroprotective agents for use in treatment of BD, have been shown to affect many of these processes. [211] [212] [213] [214] [215] Monoamine, glutamate, mitochondrial, inflammatory, and other systems related to the pathophysiology of BD are interdependent. ATP derived from glucose in brain mitochondria is essential for all other cellular processes and mitochondria play a key role also in regulation of apoptosis, oxidative stress, and calcium homeostasis. This leads to the tendency to assign new hypotheses of BD, such as mitochondrial. It is hypothesized that the main contributors to neuroprogression in BD include lower levels of BDNF, decreased neurogenesis, increased neuronal and glial cell death, higher excitotoxicity from excess of glutamate and lower GABA signaling, mitochondrial dysfunction, oxidative stress, and neuroinflammation. 216 Intracellular calcium regulates multiple neuronal functions, including synaptic transmission, neuronal plasticity and survival, and neurotoxicity. 66, 217 Uptake and release of cytosolic calcium ions are included in basic mitochondrial functions and participate in the control of cellular Ca 2+ -signals. Calcium-phosphate complex in the mitochondrial matrix buffers the free Ca 2+ and regulates calciumdependent processes in cytosol. Excess of matrix Ca 2+ causes the mitochondrial permeability transition, 218 which leads to inhibition of oxidative phosphorylation, inhibition of citric acid cycle enzymes, decrease of ATP synthesis, increase of ROS production, and release of calcium and apoptogenic factor into cytosol. 219 The calcium and mitochondrial dysfunction hypothesis of BD posits that mtDNA polymorphisms/mutations or mtRNA deletions caused by nuclear gene mutations can cause mitochondrial dysregulation of Ca 2+ leading to symptoms of BD.
220-222
INTEGRATED NEUROBIOLOGY OF BD
Recently, the complexity of BD has been emphasized based on the fact that various biological studies provide a different perspective on BD as a biologically diverse disease category. 18 Genetic studies have confirmed the polygenic model of BD with a large number of genes with small effects, modified by epistasis, epigenetics, and environment. Structural and functional imaging findings have shown a compromised integrity of frontal-subcortical and prefrontal-limbic circuits in BD. Changes in the immune system of BD patients are associated with changes in glial and neuronal functions, disturbed monoaminergic and glutamatergic neurotransmission, and impaired neuroplasticity. An association has been confirmed between BD and circadian rhythm disturbances. Alterations in HPA axis activity in BD lead to elevation of circulating cortisol; moreover, elevated inflammatory cytokines may desensitize glucocorticoid receptors in mood disorders. The inflammatory mediators released by activated microglia in response to peripheral inflammatory signals may induce the release of ATP and cytokines by astrocytes, which form a positive feedback loop and further release of inflammatory cytokines from microglia. Moreover, activated astrocytes may be responsible for glutamate excitotoxicity. Activated microglia may increase IDO activity and the TRYCAT pathway, which contribute to neurotoxicity and disturbed serotonin signaling. Decreased expression of the neurotrophin BDNF has been confirmed in both depressive and manic/hypomanic episodes, which may be responsible for disturbances in release of serotonin, glutamate, and GABA in brain structures included in pathophysiology of BD, such as cerebral cortex and hippocampus. There is a reciprocal relationship between BDNF and pro-inflammatory cytokines in BD. Mitochondrial dysfunction has been supposed to be responsible for disturbances in bioenergetics, calcium homeostasis, and ROS production in BD.
The integrated monoamine, neurotrophin, and cytokine hypothesis is based on reciprocal regulation of key components of these pathways: 5-HTT, BDNF, and pro-inflammatory cytokines. 223 The model supposes that: (i) under depression, stress, or inflammation, microglial cells and astrocytes become activated and release pro-inflammatory cytokines; (ii) cytokine-and stress-dependent pathways enhance 5-HTT activity, as well as increase 5HTT gene expression; (iii) increased 5-HTT activity results in a reduction of extracellular serotonin levels and decreased activation of pre-and postsynaptic serotonin receptors; (iv) CREB-dependent BDNF gene expression is reduced and BDNF levels are decreased, which leads to disturbed neuroplasticity and to depression-associated alteration of specific brain circuits.
THERAPEUTIC HYPOTHESES
The biological mechanism involved in the etiology of BD, such as monoaminergic dysfunctions, altered glutamatergic neurotransmission, mitochondrial dysfunction and oxidative stress, increased inflammation, impaired cell signaling (inositol monophosphatase, GSK-3, PKC, calcium channels) and apoptosis, decreased neurogenesis, changed activation of corticolimbic emotion control circuits, disturbed sleep and circadian regulation, and psychosocial variables, all facilitate the search for new therapeutics and understanding the mechanisms of their action. 224, 225 Conversely, the mechanisms of action of drugs used to treat BD or that are able to induce a switch between episodes of the disease provide the foundation for the formulation of new biological hypotheses or evidence to confirm existing hypotheses.
Several reviews of the management of BD have been published. [226] [227] [228] The therapeutic approach differs considerably for mania/hypomania, depression, and euthymia. Pharmacological medication also differs between maintenance and the acute mood episode. 227, 229 Overall, antipsychotic drugs (haloperidol, risperidone, and olanzapine mainly) were significantly more effective than mood stabilizers in treatment of acute mania. 226, 230 Olanzapine plus fluoxetine, and quetiapine, were the most efficacious treatment drugs for bipolar depression. 227, 231 In view of the efficacy in prevention of both manic and depressive episodes relapse and recurrence, lithium was recommended in the firstline treatment in patients with BD. 232, 233 New putative treatment of BD should be based on drug-induced modulation of multiple intracellular targets included in pathophysiology of BD: dopamine system, glutamate receptors, oxidative stress, mitochondrial functions, neuroprotective factors, inflammatory pathways, and sleep and circadian rhythms.
Drugs acting through glutamate signaling pathways, such as ketamine, could be used for treatment of the depressive episode. 55 Currently, several new drugs exploring the glutamate pathway are in development. 225 Patients with BD treated with lithium have reduced lipid peroxidation (TBARS), which indicates antioxidant effects of lithium in the prevention of BD progression and clinical efficiency. 234, 235 Antioxidants, such as N-acetylcysteine (NAC) seem to be beneficial in treatment of both major depressive episodes 236 and manic/hypomanic episodes. 237 NAC is a promising novel therapeutic option for BD and other neuropsychiatric disorders, because NAC targets glutamatergic transmission, glutathione, neurotrophins, apoptosis, mitochondrial function, and inflammatory pathways. 238 Recent studies have provided data about the positive effects of chronic treatment by mood stabilizers on mitochondrial functions. 203, 239 Lithium increased the activity of electron transport chain complexes I, II and III. 240 Lithium and valproate enhanced mitochondrial function (respiration rate, membrane potential, and mitochondrial oxidation), protected against mitochondria-mediated methamphetamine-induced toxicity, 241 and stabilized intracellular calcium dynamics. Therefore, it is expected that new drugs aimed at regulation of mitochondrial function might be effective in the treatment of BD.
Impairments in neuroprotective, neurotrophic, cellular plasticity, and resilience pathways have been found to be associated with BD. Promising therapeutic strategies for treatment of BD include prevention, treatment, or rectifying of these pathophysiological changes. Lithium is targeted to various factors in survival, neurotrophic, and neuroprotective pathways, such as neurotrophic factors, MAPK, phosphoinositide signaling, intracellular calcium, glutamate activity, antiapoptotic factor Bcl-2, and proapoptotic GSK-3. 232, [242] [243] [244] [245] Putative neuroprotective agents for BD include beyond lithium other known psychotropics (clozapine, aripiprazole, olanzapine, ziprasidone, and antidepressants), NAC, aspirin, leptin, omega-3 polyunsaturated fatty acids, and melatonin. 211 Based on the inflammation/microglia hypothesis, anti-inflammatory agents are potential drugs for treatment BD (i.e., the immune system seems to be a target of drugs developed for treatment of BD and antidepressant effect of anti-inflammatory drugs has been tested). Lithium ameliorates lipopolysaccharideinduced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/ FoxO1 pathway. 246 The anti-inflammatory effect of valproate seems to be based on induction of apoptosis Neuroimaging Grey matter reduction in left rostral anterior cingulate cortex and right fronto-insular cortex thickness 13, 14, 16 Volumetric reductions of mean hippocampus and thalamus; enlarged lateral ventricles 12, 17 Increased rates of deep white matter hyperintensities 15 Increased activation in ventral limbic regions in response to emotional stimuli 257 Overactivation of amygdala, striatum, and thalamus 19, 20 Biochemistry Neurotrophic factors
Decreased BDNF [71] [72] [73] [74] [75] [76] 78 Lower GDNF 70 Elevated VEGF 70, 105, 106 Immune parameters Elevated IL-1β, IL-6, TNF-α, IL-2, IL-6, IL-10, sIL-2R, sIL-6R, sTNFR1, IL-4, IL-1RA, IL-1β, IFN-γ, vWf [146] [147] [148] [149] [150] [151] 154, [156] [157] [158] [159] Elevated S100B 141, 142 Elevated C-reactive protein 152, 153 Increased kynurenine and TDO [171] [172] [173] [174] Matrix metalloproteinase 9, matrix metalloproteinase 7 165, 166 Neurotransmitter systems Elevated MAO-A, reduced 5-HTT [46] [47] [48] Lower DAT availability 51, 52 Reduced muscarinic acetylcholine M 2 receptor binding 53 Elevated brain glutamate + glutamine levels 57 Mitochondrial dysfunction
Reduced activity of mitochondrial complexes (complex I mainly) 35, [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] 208, 209 Mitochondrial morphology Decreased high-energy phosphates, elevated lactate, decreased pH Decreased NAA 210 Oxidative stress Increased TBARS (lipid peroxidation) 3, 141, 175, [190] [191] [192] [193] 195 Increased NO activity Increased DNA/RNA damage Neuroendocrine factors
Increased cortisol [160] [161] [162] C-peptide, insulin, peptide YY 247 Adjunctive treatment with celecoxib, a COX-2 inhibitor, may produce a rapid-onset antidepressant effect in BD patients experiencing depressive or mixed episodes. 248 Aspirin, a nonsteroidal anti-inflammatory drug that is an irreversible inhibitor of both COX-1 and COX-2 (it stimulates endogenous production of anti-inflammatory regulatory signals), is a potential new therapy for a range of neuropsychiatric disorders, including BD. 249 The antidepressant efficacy of minocycline, a drug inhibiting microglia activation and showing neuroprotective and immune-modulating properties, and of aspirin as an adjunctive treatment, has been evaluated in BD. 250 A meta-analysis confirmed a moderate antidepressant effect for various adjunctive anti-inflammatory agents compared with conventional therapy alone in the treatment of BD. 251 Efficiency of antipsychotics in BD treatment emphasizes the role of regulation of the dopamine system; however, the intrinsic anti-inflammatory and immunomodulatory effects of antipsychotic drugs have been known for a long time. 252 In vitro studies have suggested the anti-inflammatory effects of recent antipsychotics on microglial activation, 253 which may contribute to their therapeutic effect in BD. For example, aripiprazole and minocycline may have antipsychotic effects through reducing oligodendrocyte damage caused by microglial activation; 254 quetiapine ameliorated the microglia activation in various brain regions of mice exposed to cuprizone. 255 Antipsychotics also target intracellular Ca 2+ signaling (controlled by the endoplasmic reticulum and mitochondria), which is important for microglial functions. 256 As a result, modulating microglia may be a novel therapeutic target in treatment of BD.
BIOMARKERS
In BD, both state markers related to various mood states (mania, depression, remission) and trait markers related to BD as such may be useful in the early diagnosis of BD, control of disease progression, and treatment response. Biomarkers can be useful in developing new medicines and treatments aimed at reversing disease-related changes. 190-193, 195,197-206,208-210,220-222,257,258 The identification of biological markers for subsets of BD may be of importance. Recently, a systematic review revealed that specific biomarkers (particularly in the field of neuroendocrine-immunology, neuroimaging, and neuropsychology) exist for psychotic BD and that psychotic BD can be considered an intermediate phenotype between schizophrenia and mood disorders. 259 A large number of plasma biomarkers were identified to be associated with distinct BD mood states. For example, plasma levels of the hormones C-peptide, progesterone, and insulin and the inflammatory protein cancer antigen 125 were altered in both manic and mixed mood states. The hormone peptide YY and the growth factor trafficking protein sortilin were changed only in manic episode. The inflammation-related factors haptoglobin, chemokine CC4, and MMP-7 were altered specifically in mixed mood state. 166 C-peptide, insulin, MMP-7, and peptide YY were also found to be changed in BD depressed patients, 258 which suggests that these proteins could be trait markers for BD. Thus, application of individual biomarkers depends on the stage of the disease.
136,260-263
SWITCHING BETWEEN EPISODES
A defining characteristic of BD is switching/cycling between the state of depression and mania/hypomania with a tendency to recur and progress. Patients with a previous history of mania/hypomania have spontaneous switch rates of 21% (mania to depression) to 29% (depression to mania); in prospective studies the rates were around 30%. 264 Currently, the term 'switch' includes both the spontaneous process, as a core feature of BD, and also treatment-emergent affective switch (TEAS). Most studies of mechanisms of the switch process in BD refer to TEAS. 265, 266 The risk of switching from mania to depression in BD has been little studied; a relatively small number (5.0%) of medicated patients with BD switch from a manic/mixed episode to depression during the 12 weeks after a manic episode. 267 
Allostatic load
Adaptive and maladaptive changes in the brain attempt to compensate for pathological neurobiological alterations in BD, which is considered an increase in the allostatic load. The concept of allostatic load has been introduced into biological hypotheses of BD, in order to explain the origin and impact of recurrent mood episodes. 268, 269 Allostatic load represents the physiological consequences of chronic exposure to fluctuating or heightened neural, neuroendocrine, or immune response that results from repeated or chronic stress. For example, glucocorticoids, when chronically in excess, initiate a series of bodily dysfunctions that include decrease in the expression of neuroprotective factors, oxidative stress, inflammation, and cortisol-related mitochondrial dysfunction. 270 Allostatic load includes epigenetic changes and modified response to external (environmental) stimuli and affects both longterm cellular processes associated with changes in gene expression and rapid changes in the function of neurons and neural circuits. The increase in allostatic load can support psychological and somatic abnormalities and can contribute to both illness progression and cycling between episodes.
Kindling model
Kindling, a progressive strengthening of neuron responses to repetitive stimulation, was used to help conceptualize how the ratio of pathological versus adaptive factors at the level of alterations in gene expression in the brain may help to determine episode recurrence or remission in BD. The kindling hypothesis [271] [272] [273] has been tested in a number of different ways; however, support for the main principle of the hypothesis that psychosocial stressors play a greater role in the initial episodes of BD, as compared in subsequent episodes, has been inconsistent (only eight of 14 studies detected a kindling effect). 274 The stress autonomy model and stress sensitization model were identified and both are frequently referred to as 'kindling.' 275 The stress autonomy model implies two parallel processes: (i) the association between stressful life events and onsets of depressive episodes weakens with each successive depressive episode such that stressors eventually no longer trigger recurrences; and (ii) depressive episodes become progressively decoupled from life stress and may emerge autonomously, without an apparent trigger. In contrast, the stress sensitization model asserts that stressors become increasingly capable of triggering depressive symptoms and a likelihood of developing depression increases with each successive depressive episode as the person becomes progressively more sensitized to stressful life events.
Neurobiology of switching
A neurobiological mechanism for the switching from depression to its opposite state, and vice versa, is still poorly understood. An important reason is that the pathophysiology of mania remains incompletely elucidated. 276 Recently, studies investigating the neurobiological mechanisms underlying cycling from one episode to another were reviewed. [277] [278] [279] [280] Evidence suggests that tricyclic antidepressants, but not selective serotonin reuptake inhibitors or MAO inhibitors, are more likely to trigger TEAS in BD patients. The role of catecholaminergic systems in the switch process has been evidenced by the observation that catecholamine depletion evokes a rebound hypomania in BD patients. Increased postsynaptic sensitivity of dopamine and norepinephrine receptors at high levels of catecholamines has also been hypothesized to trigger switch to manic episode in BD patients. 278 Dopaminergic agonists, such as psychostimulants, and precursors of catecholamines, such as L-DOPA, have been associated with TEAS. 281, 282 It was concluded that switch to mania/ hypomania is associated with increased catecholaminergic neurotransmission (and maybe activation of the GSK-3 and PKC pathways), at least for some BD patients. However, the common precise mechanism underlying sudden spontaneous switching between episodes in BD remains unrecognized.
Dysfunctions in GABAergic and glutamatergic systems are included in the pathophysiology and treatment of BD; 55, 115 however, it is not clear if modulation of glutamate receptors might participate in the switching process. An adrenergic-cholinergic balance hypothesis of BD, which is based on inhibitory effect of extracellular acetylcholine on dopamine and norepinephrine activity, proposes that increased cholinergic functioning underlies depression, whereas increased catecholaminergic functioning underlies mania. 283, 284 Any factor causing an imbalance between cholinergic and adrenergic systems was hypothesized to trigger manic/hypomanic switching in BD. 285 According to the revised balance hypothesis of BD, 284 the following factors have a potential to switch to and from depression and mania/ hypomania through disturbance of catecholaminergic-cholinergic balance: (i) stress or inhibitors of acetylcholinesterase activity, an action that results in depression due to acetylcholineinduced decrease of catecholaminergic activity; (ii) activators of tyrosine hydroxylase activity (e.g. increased photoperiod exposure), an action that results in a switch to manic/hypomanic episode due to increased biosynthesis of catecholamines; and (iii) factors altering susceptibility to external stimuli, such as polymorphisms in the gene for DAT or the CLOCK gene.
Sleep deprivation may induce rapid spontaneous switch from depression into mania/hypomania in BD. 286 Processes associated with sleep deprivation seem to be closest to the neurobiology of spontaneous switching. It has been suggested that rapid-eyemovement sleep deprivation causes activation of the noradrenergic system (by blockade α 2 autoreceptors in locus coeruleus), resulting in the rapid increase of expression and activity of transcription factor CREB, neurotrophin BDNF, and its receptor TrkB, which may lead to the switch into mania/hypomania. 73, 75, 278, 287 According to the circadian rhythm hypothesis, circadian rhythm instability and the dysregulation of the HPA axis and monoamine systems may increase individual susceptibility for switching from depression to mania/hypomania. 288 In conclusion, it appears that polymorphisms in the CLOCK gene, along with sleep disruption and resulting increase of CREB, BDNF, and TrkB, might be decisive factors in the induction of the switch to manic/hypomanic episode in BD patients. 278, 287 We suppose that disturbed activities of signaling pathways regulated by monoamine neurotransmitters and BDNF (including MAPK/ERK, PI3K/Akt, IP 3 / DAG, and GSK-3) participate in the switching mechanism and the immediate stimulus for the switching depends on the individual status of neurotransmitter signaling pathways and allostatic load. Immediate switching stimulus can come from disruption of circadian and other chronobiological rhythms and/or from the activation of the immunoneuroendocrine system by stress or by inflammation.
CONCLUSION
Extended biological hypotheses have been proposed to explain the role of several biomarkers for mood disorders and to test the probable causality of molecular processes responsible for disturbed storage, retrieval, and processing of information in the brain and disturbed function of specific neuronal circuits during episodes of BD. These hypotheses have been put in the context of changes in genetics, structure, function, physiology, and neurochemistry of the brain in BD, primarily changes in neuroplasticity, neuroinflammation, intracellular signaling pathways, bioenergetics, oxidative and nitrosative stress, apoptosis and proteolysis, calcium signaling, and membrane or vesicular transport. Future studies are expected to confirm the integrated models involving the correct causality of these processes in the development of BD or switching between episodes. Specific biomarkers for BD could lead to an early diagnosis and proper treatment of the disease; although they are promising, they need to be verified in replicated studies.
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